News coverage about Nabriva Therapeutics AG (NASDAQ:NBRV) has trended somewhat positive on Friday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nabriva Therapeutics AG earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.1271496616778 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

NBRV has been the topic of several research reports. Zacks Investment Research raised shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a research note on Wednesday, October 11th. Cantor Fitzgerald reissued a “buy” rating and set a $16.00 price target on shares of Nabriva Therapeutics AG in a research note on Friday, September 1st. HC Wainwright reissued a “buy” rating and set a $18.00 price target (up from $16.00) on shares of Nabriva Therapeutics AG in a research note on Monday, August 28th. SunTrust Banks, Inc. lifted their price target on shares of Nabriva Therapeutics AG from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, September 18th. Finally, Wedbush reissued an “outperform” rating and set a $21.00 price target (up from $13.00) on shares of Nabriva Therapeutics AG in a research note on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $19.03.

Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) traded up $0.56 during midday trading on Friday, hitting $6.56. 556,300 shares of the company traded hands, compared to its average volume of 270,004. Nabriva Therapeutics AG has a 12 month low of $4.00 and a 12 month high of $14.10.

In related news, major shareholder Hbm Healthcare Investments (Ca sold 36,608 shares of Nabriva Therapeutics AG stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $8.56, for a total value of $313,364.48. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Vivo Capital Viii, Llc bought 52,631 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was purchased at an average cost of $9.46 per share, for a total transaction of $497,889.26. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 57,219 shares of company stock worth $535,919. 2.75% of the stock is owned by insiders.

WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/nabriva-therapeutics-ag-nbrv-given-daily-coverage-optimism-score-of-0-11/1723905.html.

About Nabriva Therapeutics AG

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with Analyst Ratings Network's FREE daily email newsletter.